Bayer inks $1.3 billion deal with Kumquat Biosciences for cancer drug development

2 hours ago 1

Bayer (OTCPK:BAYZF) on Tuesday unveiled a partnership deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia

Recommended For You